TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06571032: HARBOR: Global Phase 3 Study of Del-desiran (AOC 1001) Antibody Oligonucleotide Conjugate in Myotonic Dystrophy Type 1 (DM1)

Sponsor: Avidity Biosciences, Inc. · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 150 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$23,401,600

Rescue Site Savings

+$15,430,430

Unlock Full NCT06571032 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06571032 Rescue Dossier →